electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance
12 avr. 2022 08h00 HE
|
electroCore, Inc.
Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021March 31, 2022, cash balance of approximately $29.9M ROCKAWAY, N.J., April 12, 2022 ...
electroCore Announces Exclusive License Agreement with Teijin for Japan Territory
05 avr. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an...
electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York
23 mars 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief...
electroCore to Present at 2022 Maxim Virtual Growth Conference
22 mars 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief...
electroCore Announces Fourth Quarter and Full Year 2021 Financial Results
10 mars 2022 16h01 HE
|
electroCore, Inc.
Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020 Ended 2021 with cash and cash equivalents of $34.7 million Company to host conference call...
electroCore Announces Changes to its Board of Directors
09 mars 2022 11h30 HE
|
electroCore, Inc.
ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein...
electroCore to Present at 34th Annual Roth Conference
07 mars 2022 16h01 HE
|
electroCore, Inc.
ROCKAWAY, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will...
electroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results on Thursday, March 10
03 mars 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
Data Presented at 2022 International Stroke Congress Suggests Role for Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Stroke
09 févr. 2022 08h00 HE
|
electroCore, Inc.
Clinical Trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative Ischemic Lesion Growth Decreased by 65.9% with nVNS vs. Sham Treatment. ROCKAWAY, N.J.,...
electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus
01 févr. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced enrollment has been completed for the TRANSIT...